Trinity Biotech reports Q4 EPS 21c, consensus 21c Reports Q4 revenue $20.8M, consensus $21.84M. The company is making significant progress in the development of its new cardiac point of care tests. With regard to Troponin I, the company is currently focusing on completing development of the test with a view to meeting the new FDA guidelines for Troponin I. The company is also preparing for the forthcoming CE marking trials which will take place at multiple sites in Europe, commencing in Q2. CE marking remains on target for Q4 after which sales in the European market will commence. FDA trials are due to commence in Q3 with submission to the FDA scheduled for 1Q14.